Intellia Therapeutics Files 8-K on Financial Condition, Other Events

TL;DR

**Intellia Therapeutics just dropped an 8-K, expect financial or operational news soon!**

AI Summary

Intellia Therapeutics, Inc. filed an 8-K on January 4, 2024, to report on its 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and 'Other Events.' This filing, under SEC File Number 001-37766, indicates that the company is providing an update on its financial status and other material information. For investors, this matters because it signals that Intellia is likely to release or has just released important financial or operational news that could impact its stock price, NTLA, on The Nasdaq Global Market.

Why It Matters

This filing indicates Intellia Therapeutics is disclosing material information, likely financial or operational, which could influence investor perception and stock valuation.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the undisclosed content it refers to could contain significant risks or opportunities for investors.

Analyst Insight

Investors should monitor Intellia Therapeutics' news releases closely for the specific details referenced by this 8-K, as they will contain the actual material information that could affect the stock price.

Key Players & Entities

• Intellia Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 4, 2024 (date) — date of earliest event reported and filing date
• 001-37766 (string) — Commission File Number for Intellia Therapeutics
• NTLA (string) — trading symbol for Intellia Therapeutics Common Stock
• The Nasdaq Global Market (string) — exchange where Intellia Therapeutics Common Stock is registered

Forward-Looking Statements

• Intellia Therapeutics will release detailed financial results or significant operational updates related to the 'Results of Operations and Financial Condition' and 'Other Events' items mentioned in the 8-K. (Intellia Therapeutics, Inc.) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
• $1.0 billion — cts to report that it had approximately $1.0 billion of cash, cash equivalents and marketabl

Filing Documents

• d655921d8k.htm (8-K) — 47KB
• d655921dex991.htm (EX-99.1) — 31KB
• g655921dsp7.jpg (GRAPHIC) — 5KB
• g655921dsp7a.jpg (GRAPHIC) — 7KB
• 0001193125-24-002438.txt ( ) — 225KB
• ntla-20240104.xsd (EX-101.SCH) — 3KB
• ntla-20240104_lab.xml (EX-101.LAB) — 18KB
• ntla-20240104_pre.xml (EX-101.PRE) — 11KB
• d655921d8k_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2023, Intellia Therapeutics, Inc. (the "Company") announced on January 4, 2024, that it expects to report that it had approximately $1.0 billion of cash, cash equivalents and marketable securities as of December 31, 2023. The information contained in Item 2.02 of this Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2023. The audit of the Company's consolidated financial statements for the year ended December 31, 2023, is ongoing and could result in changes to the information set forth above. The information in this Item 2.02 is being furnished herewith and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing .

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 4, 2024, the Company issued a press release titled "Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information under this Item 7.01, including Exhibit 99.1 hereto, are being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Other Events

Item 8.01. Other Events. On January 4, 2024, the Company announced its strategic priorities through 2026 and key anticipated 2024 milestones that support the Company's mission to transform the lives of patients and bring forth a new era in medicine. Recent Pipeline Advancement and Corporate Updates NTLA-2001 for Transthyretin (ATTR) Amyloidosis: Initiated and actively enrolling the pivotal Phase 3 MAGNITUDE trial in adults with ATTR amyloidosis with cardiomyopathy (ATTR-CM). NTLA-2002 for Hereditary Angioedema (HAE): Completed enrollment and dosing in the Phase 2 portion of the Phase 1/2 study in adults with HAE. NTLA-3001 for Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease: Submitted a clinical trial application to initiate a first-in-human Phase 1 study of NTLA-3001 ahead of previous Q1 2024 expectation. Organizational Streamlining: Following an internal strategic review, the Company will be streamlining company-wide operations to further focus resources on key strategic priorities and programs. These changes will result in a pause of select exploratory research-stage programs and a workforce reduction of approximately 15%. Cash Runway: The Company ended the fourth quarter of 2023 with approximately $1.0 billion in cash, cash equivalents and marketable securities. The cash position is expected to fund operations into mid-2026. Board Update: In December, the Company announced the departure of John Crowley from its board of directors following his appointment as Chief Executive Officer of the Biotechnology Innovation Organization (BIO), the life sciences industry's leading trade and advocacy association. 2024 – 2026 Strategic Priorities 1. Complete patient enrollment for pivotal studies of NTLA-2001 and NTLA-2002 , including planned biologics license application (BLA) submission for NTLA-2002 in 2026; 2. Launch clinical trials for next wave of in vivo and ex vivo programs , validating CRISPR-based in vivo targeted gene insertion

Forward Looking Statements

Forward Looking Statements. This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding the Company's beliefs and expectations regarding: its ability to expand and validate its industry-leading gene editing platform, including the advancement of novel gene editing technologies, such as DNA writing, and delivery to other tissues outside of the liver; the safety, efficacy, success and advancement of its clinical programs for NTLA-2001 for the treatment of transthyretin ("ATTR") amyloidosis, NTLA-2002 for the treatment of hereditary angioedema ("HAE"), and NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency ("AATD")-associated lung disease, including the expected timing of data releases, regulatory filings, and the initiation, dosing, and completion of clinical trials, such as the dosing of the first patient in the pivotal Phase 3 MAGNITUDE trial of NTLA-2001 for ATTR amyloidosis with cardiomyopathy ("ATTR-CM") in Q1 2024, the preparation for a Phase 3 study of NTLA-2001 for the treatment of ATTR amyloidosis with polyneuropathy ("ATTRv-PN") in 2024, the presentation of updated clinical data from the ongoing Phase 1 study of NTLA-2001 in 2024, the initiation of a global pivotal Phase 3 trial of NTLA-2002 in 2H 2024, the presentation of additional data from the Phase 1/2 trial of NTLA-2002 in 2024, the submission of a biologics license application for NTLA-2002 in 2026, and the dosi

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: January 4, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR